NCT01146327View on ClinicalTrials.gov

A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Healthy
Interventions
DRUG

PF-04620110

Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.

DRUG

PF-04620110

Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.

DRUG

PF-04620110

Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.

DRUG

PF-04620110

Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.

DRUG

Placebo

Multiple oral doses of placebo will be given once daily for 2 weeks.

Trial Locations (2)

188770

Pfizer Investigational Site, Singapore

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Pfizer

INDUSTRY